1027 related articles for article (PubMed ID: 34755538)
1. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D
Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538
[TBL] [Abstract][Full Text] [Related]
2. Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches.
Watashi K
Biochem Biophys Res Commun; 2021 Jan; 538():137-144. PubMed ID: 33272566
[TBL] [Abstract][Full Text] [Related]
3. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV.
Scroggs SLP; Offerdahl DK; Flather DP; Morris CN; Kendall BL; Broeckel RM; Beare PA; Bloom ME
Viruses; 2020 Dec; 13(1):. PubMed ID: 33374514
[TBL] [Abstract][Full Text] [Related]
5. Entrectinib-A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells.
Peralta-Garcia A; Torrens-Fontanals M; Stepniewski TM; Grau-Expósito J; Perea D; Ayinampudi V; Waldhoer M; Zimmermann M; Buzón MJ; Genescà M; Selent J
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948390
[TBL] [Abstract][Full Text] [Related]
6. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
Andreani J; Le Bideau M; Duflot I; Jardot P; Rolland C; Boxberger M; Wurtz N; Rolain JM; Colson P; La Scola B; Raoult D
Microb Pathog; 2020 Aug; 145():104228. PubMed ID: 32344177
[TBL] [Abstract][Full Text] [Related]
7. Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies.
Kutkat O; Moatasim Y; Al-Karmalawy AA; Abulkhair HS; Gomaa MR; El-Taweel AN; Abo Shama NM; GabAllah M; Mahmoud DB; Kayali G; Ali MA; Kandeil A; Mostafa A
Sci Rep; 2022 Jul; 12(1):12920. PubMed ID: 35902647
[TBL] [Abstract][Full Text] [Related]
8. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
[TBL] [Abstract][Full Text] [Related]
9. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
Mishra J; Prasun C; Sahoo PK; Nair MS
Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
[TBL] [Abstract][Full Text] [Related]
10. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
11. Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19.
Ko M; Chang SY; Byun SY; Ianevski A; Choi I; Pham Hung d'Alexandry d'Orengiani AL; Ravlo E; Wang W; Bjørås M; Kainov DE; Shum D; Min JY; Windisch MP
Viruses; 2021 Apr; 13(4):. PubMed ID: 33918958
[TBL] [Abstract][Full Text] [Related]
12. From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?
Rakedzon S; Neuberger A; Domb AJ; Petersiel N; Schwartz E
J Travel Med; 2021 Feb; 28(2):. PubMed ID: 33480414
[TBL] [Abstract][Full Text] [Related]
13. Valinomycin as a potential antiviral agent against coronaviruses: A review.
Zhang D; Ma Z; Chen H; Lu Y; Chen X
Biomed J; 2020 Oct; 43(5):414-423. PubMed ID: 33012699
[TBL] [Abstract][Full Text] [Related]
14. Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies.
Vaz ES; Vassiliades SV; Giarolla J; Polli MC; Parise-Filho R
Eur J Clin Pharmacol; 2023 Jun; 79(6):723-751. PubMed ID: 37081137
[TBL] [Abstract][Full Text] [Related]
15. Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
Akilesh SM; J R; Palanisamy D; Wadhwani A
Curr Pharm Biotechnol; 2021; 22(2):192-199. PubMed ID: 32867651
[TBL] [Abstract][Full Text] [Related]
16. A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2.
Das M; Kumar M; Jha A; Madhukiran DR; Bharti K; Mondal S; Mishra B
Curr Drug Targets; 2021; 22(11):1232-1254. PubMed ID: 33371846
[TBL] [Abstract][Full Text] [Related]
17. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus.
Terrier O; Dilly S; Pizzorno A; Chalupska D; Humpolickova J; Bouřa E; Berenbaum F; Quideau S; Lina B; Fève B; Adnet F; Sabbah M; Rosa-Calatrava M; Maréchal V; Henri J; Slama-Schwok A
Molecules; 2021 Apr; 26(9):. PubMed ID: 33946802
[TBL] [Abstract][Full Text] [Related]
18. High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.
Choi R; Zhou M; Shek R; Wilson JW; Tillery L; Craig JK; Salukhe IA; Hickson SE; Kumar N; James RM; Buchko GW; Wu R; Huff S; Nguyen TT; Hurst BL; Cherry S; Barrett LK; Hyde JL; Van Voorhis WC
PLoS One; 2021; 16(4):e0250019. PubMed ID: 33886614
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2.
Tummino TA; Rezelj VV; Fischer B; Fischer A; O'Meara MJ; Monel B; Vallet T; White KM; Zhang Z; Alon A; Schadt H; O'Donnell HR; Lyu J; Rosales R; McGovern BL; Rathnasinghe R; Jangra S; Schotsaert M; Galarneau JR; Krogan NJ; Urban L; Shokat KM; Kruse AC; García-Sastre A; Schwartz O; Moretti F; Vignuzzi M; Pognan F; Shoichet BK
Science; 2021 Jul; 373(6554):541-547. PubMed ID: 34326236
[TBL] [Abstract][Full Text] [Related]
20. Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities.
Wehbe Z; Wehbe M; Iratni R; Pintus G; Zaraket H; Yassine HM; Eid AH
Front Immunol; 2021; 12():663586. PubMed ID: 33859652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
